Corindus Vascular Robotics, Inc. announced today the opening of the first international CorPath GRX Robotic Center in Tokyo, Japan. Earlier this year, Corindus partnered with Japan Medicalnext Co., Ltd., a wholly-owned entity of MC Healthcare, Inc. (subsidiary of Mitsubishi Corporation), to become the exclusive distributor of Corindus products in Japan, bringing robotic-assisted percutaneous coronary interventions (PCI) to the Japanese market. The first three CorPath GRX Systems were shipped to Japan Medicalnext by July and will be used at its newly constructed robotic center according to Japan’s regulation.
Tal Wenderow, Co-Founder and Executive Vice President of International and Business Development of Corindus said, “The opening of the first international robotic center represents an important milestone in the process of bringing precision vascular robotics to patients and physicians in Japan, and around the world. He added, “Japan is the third largest PCI market with approximately 250,000 annual procedures, and is an important market as we grow our business internationally. We look forward to introducing our technology to the Japanese cardiology community.”
The company states that the robotic center and robotic simulation lab will be used to educate interventional cardiologists on the benefits of robotic-assisted PCI procedures. CorPath GRX is the second generation robotic-assisted PCI technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically.
“Robotic-assisted PCI is a natural extension of our current capabilities and will fit well within our current practice,” said Takafumi Ueno, MD, PhD, Director of Interventional Cardiology, Center of Cardiovascular Disease, Kurume University Hospital. “I look forward to seeing the positive impact the CorPath GRX System will have on patients and physicians.”
In preparation for commercial launch of CorPath GRX in Japan, the Company is working with Japan Medicalnext to secure Pharmaceutical and Medical Device Agency (PMDA) approval.